Clinical Trials
32
Active:28
Completed:3
Trial Phases
3 Phases
Phase 1:28
Phase 2:2
Phase 3:1
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (31 trials with phase data)• Click on a phase to view related trials
Phase 1
28 (90.3%)Phase 2
2 (6.5%)Phase 3
1 (3.2%)No trials found
News
Phase 3 ROSELLA Trial Explores Relacorilant to Combat Chemoresistance in Ovarian Cancer
The ROSELLA trial is evaluating relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel for platinum-resistant ovarian cancer.
Corcept Completes Enrollment in Phase III Ovarian Cancer Study of Relacorilant
Corcept Therapeutics has completed enrollment in the Phase III ROSELLA study evaluating relacorilant plus Abraxane for recurrent, platinum-resistant ovarian cancer.